See more : Linde India Limited (LINDEINDIA.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Cresco Labs Inc. (CRLBF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cresco Labs Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Aegon N.V. (AEGOF) Income Statement Analysis – Financial Results
- LifeSci Acquisition II Corp. (LSAQ) Income Statement Analysis – Financial Results
- Nihon Trim Co., Ltd. (6788.T) Income Statement Analysis – Financial Results
- JSL Construction & Development Co., Ltd. (2540.TW) Income Statement Analysis – Financial Results
- Rennova Health, Inc. (RNVAW) Income Statement Analysis – Financial Results
Cresco Labs Inc. (CRLBF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.crescolabs.com
About Cresco Labs Inc.
Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand, as well as cannabis products under the Reserve brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections, fruit-forward gummies, hard sweets, and taffy under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. As of January 27, 2022, it owned and operated 48 dispensaries. The company was founded in 2013 and is headquartered in Chicago, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 770.89M | 842.68M | 821.68M | 476.25M | 128.53M | 43.25M | 10.31M | 3.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 441.00M | 435.67M | 415.34M | 192.31M | 64.45M | 2.84M | 9.16M | 14.57 | 61.11 | 82.81 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 329.89M | 407.01M | 406.35M | 283.94M | 64.08M | 40.42M | 1.15M | 3.16M | -61.11 | -82.81 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 42.79% | 48.30% | 49.45% | 59.62% | 49.86% | 93.45% | 11.17% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 1.99M | 370.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 36.81M | 54.99M | 40.34M | 160.94M | 77.15M | 29.16M | 44.42K | 42.84K | 49.32K | 49.32K | 205.78K | 341.29K | 311.56K | 338.34K | 439.16K | 300.52K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 8.30M | 15.58M | 29.73M | 19.03M | 12.63M | 2.05M | 455.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.45K | 8.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 31.81K | 16.46K |
| SG&A | 259.81M | 350.65M | 317.80M | 179.97M | 89.78M | 31.21M | 44.42K | 42.84K | 49.32K | 49.32K | 205.78K | 341.29K | 311.56K | 338.34K | 440.60K | 308.96K | 673.66K | 442.67K | 1.56M | 437.22K | 244.28K | 130.92K | 45.36K | 31.81K | 16.46K |
| Other Expenses | 151.02M | -572.00K | 753.00K | 48.13M | 8.56M | 27.00K | 663.85 | 9.23K | 9.91K | 9.09K | 53.77K | 70.09K | 227.95K | 253.46K | 22.40K | -303.78K | 1.07K | 21.70K | 766.91 | 1.16K | -119.15K | 127.65K | 209.13K | 319.18K | 231.94K |
| Operating Expenses | 435.36M | 350.08M | 318.56M | 228.10M | 98.34M | 33.82M | 44.42K | 42.86K | -55.99K | 60.27K | 208.32K | 380.51K | 339.52K | 338.89K | 440.98K | 310.51K | 674.73K | 444.15K | 1.56M | 441.25K | 244.28K | 130.92K | 89.48K | 350.99K | 248.41K |
| Cost & Expenses | 858.71M | 785.75M | 733.89M | 420.41M | 162.79M | 36.65M | 44.42K | 42.86K | -55.99K | 60.27K | 208.32K | 380.51K | 339.52K | 338.89K | 440.98K | 310.51K | 674.73K | 444.15K | 1.56M | 441.25K | 244.28K | 130.92K | 89.48K | 350.99K | 248.41K |
| Interest Income | 2.42M | 679.00K | 938.00K | 1.41M | 1.58M | 89.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.96K | 18.40K | 0.00 | 1.56K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 63.24M | 58.52M | 52.15M | 40.91M | 9.46M | 89.00K | 41.60K | 30.81K | 26.49K | 33.62K | 48.18K | 39.92K | 39.75K | 49.55K | 32.63K | 3.78K | 0.00 | 1.10M | 0.00 | 0.00 | 182.35K | 0.00 | 0.00 | 132.58K | 0.69 |
| Depreciation & Amortization | 70.57M | 55.44M | 44.55M | 38.70M | 12.19M | 2.17M | 646.00K | 14.57 | 61.53 | 82.48 | 116.50 | 158.61 | 194.51 | 542.64 | 374.50 | 1.55K | 1.07K | 1.49K | 766.91 | 1.61 | 126.41K | 1.31 | 44.13K | 46.75K | 34.57K |
| EBITDA | -14.62M | -10.24M | -157.04M | 6.75M | -30.09M | 9.66M | -3.48M | -33.61K | 73.43K | -84.07K | -154.56K | -322.46K | 4.52K | -2.23M | -2.88M | -2.03M | -559.24K | -979.09K | -1.56M | -441.25K | -181.08K | -130.92K | -31.58K | -304.24K | -213.84K |
| EBITDA Ratio | -1.90% | 14.65% | 16.18% | 20.65% | -13.77% | 23.84% | -0.42% | -1.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -87.82M | 65.75M | 87.97M | 58.31M | -34.26M | 4.95M | -44.42K | -33.63K | 65.89K | -51.18K | -154.55K | -310.43K | -379.27K | -388.43K | -473.61K | -595.88K | -674.73K | -1.00M | -1.56M | -441.25K | -307.49K | -130.92K | -103.26K | -350.99K | -248.41K |
| Operating Income Ratio | -11.39% | 7.80% | 10.71% | 12.24% | -26.65% | 11.43% | -0.43% | -1.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -59.08M | -42.61M | -39.38M | -40.71M | -28.95M | -1.29M | 139.77K | 53.05K | 96.42K | -56.92K | 5.59K | 20.51K | 186.63K | -1.89M | -2.44M | -1.72M | 90.18K | -537.39K | 43.16K | 1.16K | -182.35K | 127.65K | 195.35K | -132.58K | -0.69 |
| Income Before Tax | -146.90M | -126.91M | -256.73M | 7.16M | -50.84M | 7.47M | -85.35K | -108.03K | 47.38K | -117.44K | -202.74K | -361.38K | -151.32K | -85.43K | -2.91M | -2.05M | -584.55K | -981.24K | -1.51M | -440.09K | -489.85K | -3.27K | 92.09K | -483.57K | -248.41K |
| Income Before Tax Ratio | -19.06% | -15.06% | -31.24% | 1.50% | -39.55% | 17.26% | -0.83% | -3.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 32.95M | 88.94M | 40.11M | 43.72M | 14.46M | 4.37M | -663.85 | 43.59K | -7.98K | 32.64K | 0.00 | 11.03K | -342.40K | 4.03M | 2.47M | -19.39K | -90.18K | 1.10M | -146.31K | -3.00K | 131.48K | -116.13K | -158.23K | 132.58K | 0.69 |
| Net Income | -175.52M | -215.84M | -296.83M | -36.56M | -65.30M | -1.92M | -85.35K | -108.03K | 47.38K | -117.44K | -202.74K | -361.38K | -36.87K | -2.28M | -2.91M | -2.03M | -584.55K | -981.24K | -1.37M | -438.25K | -438.97K | -14.79K | 82.52K | -483.57K | -248.41K |
| Net Income Ratio | -22.77% | -25.61% | -36.13% | -7.68% | -50.81% | -4.43% | -0.83% | -3.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.54 | -0.72 | -1.13 | -0.17 | -0.55 | -0.03 | -2.45 | -3.10 | 1.16 | -3.38 | -5.82 | -10.38 | -1.11 | -77.44 | -108.25 | -78.24 | -24.14 | -44.38 | -71.04 | -29.14 | -43.91 | -1.76 | 15.37 | -86.80 | -67.23 |
| EPS Diluted | -0.54 | -0.72 | -1.13 | -0.17 | -0.55 | -0.03 | -2.45 | -3.10 | 1.16 | -3.37 | -5.82 | -10.38 | -1.11 | -77.44 | -108.25 | -78.24 | -24.14 | -44.38 | -71.04 | -29.14 | -43.91 | -1.76 | 15.37 | -86.80 | -67.23 |
| Weighted Avg Shares Out | 323.82M | 298.16M | 262.33M | 210.47M | 118.32M | 59.34M | 34.79K | 34.79K | 34.79K | 34.79K | 34.81K | 34.81K | 33.17K | 29.39K | 26.89K | 25.89K | 24.21K | 22.11K | 19.24K | 15.04K | 10.00K | 8.38K | 6.21K | 5.57K | 3.70K |
| Weighted Avg Shares Out (Dil) | 323.82M | 298.16M | 262.33M | 210.47M | 118.32M | 59.34M | 34.81K | 34.81K | 34.81K | 34.81K | 34.81K | 34.81K | 33.17K | 29.39K | 26.89K | 25.89K | 24.21K | 22.11K | 19.24K | 15.04K | 10.00K | 8.38K | 6.21K | 5.57K | 3.70K |
Cannabis Champions: March 2024's Top Performing US Stocks
This week, several top US marijuana stocks have caught the attention of investors and traders alike. With the US cannabis industry poised for significant growth, these companies stand out for their innovative approaches and strategic market positions. The industry's expansion...
2 Cannabis Stocks to Buy Hand Over Fist in March
A lack of progress on marijuana reform has put the cannabis industry on the back burner for many growth investors. Both Cresco Labs and Green Thumb Industries trade at low revenue multiples.
Cresco Labs to Report Fourth Quarter and Annual 2023 Financial Results on March 13, 2024
CHICAGO--(BUSINESS WIRE)--CRESCO LABS TO REPORT FOURTH QUARTER AND ANNUAL 2023 FINANCIAL RESULTS ON MARCH 13, 2024.
Cannabis stocks rise as Germany takes ‘first big step' toward broader legalization in Europe
Curaleaf Holdings Inc. Executive Chairman Boris Jordan and other cannabis executives on Friday praised Germany's removal of cannabis from a list of narcotics as a potential boost to the marijuana business, as stocks in the sector rose.
These 3 Marijuana Stocks to Buy Could Be The Ones You Want
Marijuana stock investors are keeping hopes high in 2024. There is a lot to be seen and done yet some things have started to take action. 2024 is an election year for the United States. What this means is some...
Cresco Labs Continues Retail Expansion in Pennsylvania with New Gettysburg Store
CHICAGO--(BUSINESS WIRE)--Cresco Labs Continues Retail Expansion in Pennsylvania with New Gettysburg Store.
Cannabis Comeback: 3 Stocks to Snag After the Bubble Burst
The cannabis sector is one that's certainly seen its boom-bust cycle play out in relatively impressive time in recent years. Now firmly in the “bust” category among many growth investors, will a resurgence in this space take hold?
Cannabis Investing 2024: 3 Top Marijuana Stocks To Watch
Starting Many off the new week we hope to see good momentum for the cannabis sector. Many of the top publicly traded cannabis companies are soon to release quarterly earnings while some already have. This could give great insight into...
Cresco Labs Announces Transfers of Super Voting Shares to Certain Directors
CHICAGO--(BUSINESS WIRE)--CRESCO LABS ANNOUNCES TRANSFERS OF SUPER VOTING SHARES TO CERTAIN DIRECTORS.
3 Cannabis Penny Stocks with Serious Potential to Make You a Millionaire
It's not hard to find cannabis penny stocks. But it's a little more challenging to find cannabis stocks that can make you a millionaire or even have the chance to turn a profit.
Source: https://incomestatements.info
Category: Stock Reports